316 related articles for article (PubMed ID: 15699457)
1. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Jung O; Brandes RP; Kim IH; Schweda F; Schmidt R; Hammock BD; Busse R; Fleming I
Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
[TBL] [Abstract][Full Text] [Related]
2. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
Imig JD; Zhao X; Zaharis CZ; Olearczyk JJ; Pollock DM; Newman JW; Kim IH; Watanabe T; Hammock BD
Hypertension; 2005 Oct; 46(4):975-81. PubMed ID: 16157792
[TBL] [Abstract][Full Text] [Related]
3. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Koeners MP; Wesseling S; Ulu A; Sepúlveda RL; Morisseau C; Braam B; Hammock BD; Joles JA
Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E691-8. PubMed ID: 21266668
[TBL] [Abstract][Full Text] [Related]
5. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.
Olearczyk JJ; Quigley JE; Mitchell BC; Yamamoto T; Kim IH; Newman JW; Luria A; Hammock BD; Imig JD
Clin Sci (Lond); 2009 Jan; 116(1):61-70. PubMed ID: 18459944
[TBL] [Abstract][Full Text] [Related]
6. Targeting arachidonic acid pathway to prevent programmed hypertension in maternal fructose-fed male adult rat offspring.
Tain YL; Lee WC; Wu KLH; Leu S; Chan JYH
J Nutr Biochem; 2016 Dec; 38():86-92. PubMed ID: 27732913
[TBL] [Abstract][Full Text] [Related]
7. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.
Sporková A; Jíchová S; Husková Z; Kopkan L; Nishiyama A; Hwang SH; Hammock BD; Imig JD; Kompanowska-Jezierska E; Sadowski J; Kramer HJ; Cervenka L
Clin Exp Pharmacol Physiol; 2014 Dec; 41(12):1003-13. PubMed ID: 25224811
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
[TBL] [Abstract][Full Text] [Related]
9. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.
Li J; Carroll MA; Chander PN; Falck JR; Sangras B; Stier CT
Front Biosci; 2008 May; 13():3480-7. PubMed ID: 18508449
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Merabet N; Bellien J; Glevarec E; Nicol L; Lucas D; Remy-Jouet I; Bounoure F; Dreano Y; Wecker D; Thuillez C; Mulder P
J Mol Cell Cardiol; 2012 Mar; 52(3):660-6. PubMed ID: 22155238
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
[TBL] [Abstract][Full Text] [Related]
12. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.
Kim IH; Nishi K; Tsai HJ; Bradford T; Koda Y; Watanabe T; Morisseau C; Blanchfield J; Toth I; Hammock BD
Bioorg Med Chem; 2007 Jan; 15(1):312-23. PubMed ID: 17046265
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Wu HF; Yen HJ; Huang CC; Lee YC; Wu SZ; Lee TS; Lin HC
J Biomed Sci; 2015 Oct; 22():94. PubMed ID: 26494028
[TBL] [Abstract][Full Text] [Related]
14. Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney.
Lee JP; Yang SH; Lee HY; Kim B; Cho JY; Paik JH; Oh YJ; Kim DK; Lim CS; Kim YS
PLoS One; 2012; 7(5):e37075. PubMed ID: 22590647
[TBL] [Abstract][Full Text] [Related]
15. Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-Δ(12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring.
Lu PC; Sheen JM; Yu HR; Lin YJ; Chen CC; Tiao MM; Tsai CC; Huang LT; Tain YL
Prostaglandins Other Lipid Mediat; 2016 Jul; 124():1-8. PubMed ID: 27210044
[TBL] [Abstract][Full Text] [Related]
16. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
Dorrance AM; Rupp N; Pollock DM; Newman JW; Hammock BD; Imig JD
J Cardiovasc Pharmacol; 2005 Dec; 46(6):842-8. PubMed ID: 16306811
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.
Certíková Chábová V; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Kujal P; Vernerová Z; Vanourková Z; Kopkan L; Kramer HJ; Falck JR; Imig JD; Hammock BD; Vanecková I; Cervenka L
Clin Sci (Lond); 2010 Feb; 118(10):617-32. PubMed ID: 20050826
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.
Simpkins AN; Rudic RD; Schreihofer DA; Roy S; Manhiani M; Tsai HJ; Hammock BD; Imig JD
Am J Pathol; 2009 Jun; 174(6):2086-95. PubMed ID: 19435785
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
[TBL] [Abstract][Full Text] [Related]
20. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats.
Huang H; Morisseau C; Wang J; Yang T; Falck JR; Hammock BD; Wang MH
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F342-9. PubMed ID: 17442729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
